Clinical trials: Rectal Cancer, Radiotherapy
Rectal Cancer
Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)
The study is a multicenter, open-label, randomized controlled clinical study, and the purpose of the study is to compare the pathological complete response rate (PCR) of patients with locally advanced rectal cancer treated with…
- Trial name
- NCT04928807
- Testing
- Short course radiotherapy sequential camrelizumab and chemotherapy
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Adult Patients With Locally Advanced Rectal Cancer Indicated to Neoadjuvant Therapy and Surgery
Postoperative Complications After Neoadjuvant Chemoradiotherapy or Short-course Radiotherapy and Total Neoadjuvant Treatment: a Multicentric Retrospective Cohort Study
The primary objective of the study is to compare the rate of postoperative complications between rectal cancer patients undergoing standard neoadjuvant chemoradiotherapy or short- course radiotherapy and patients receiving TNT.
- Trial name
- POCAT (NCT07346248)
- Testing
- Chemoradiotherapy
- Where
- Italy
- Volunteers
- 266 people
- Sponsor
- Istituto Clinico Humanitas
Rectum Cancer, Rectal Cancer
Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
This project investigates the clinical and biological impact of combining immunotherapy (pembrolizumab) with short course radiotherapy (5Gy, five times) in the neo-adjuvant treatment of localised microsatellite stable (MSS)…
- Trial name
- PEMREC (NCT04109755)
- Testing
- Pembrolizumab
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- University Hospital, Geneva
Anal Cancer
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00093379
- Testing
- Capecitabine, Oxaliplatin, Radiation Therapy (XRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Rectal Cancer, Radiation Oncology
Higher Radiation Dose to the Tumor May Help Avoid Surgery in Rectal Cancer Patients
The goal of this prospective study is to evaluate if a higher radiation dose to the tumor can increase the organ preservation rate in non-locally advanced rectal cancer.
- Trial name
- REBOOT (NCT07616297)
- Testing
- Simultaneous integrated boost to the tumor and positive mesorectal lymph nodes
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Claudia Schuurhuizen
Colorectal Cancer, Colorectal Neoplasms
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
Background: T-cells are white blood cells that can find and kill germs and tumors. Cancer can keep T-cells from working. Researchers think a new drug called AMP-224 might help the T-cells in people with cancer.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma
- Trial name
- NCT02298946
- Testing
- AMP-224, Stereotactic Body Radiation Therapy(SBRT), Cyclophosphamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Rectum
Optimization of Preoperative Treatment in Locally Advanced Rectal Cancer
The purpose of this study is to compare effectiveness of short-term radiotherapy with neoadjuvant chemotherapy(TNT group) with preoperative long-term chemoradiotherapy(CRT group) in locally advanced rectal cancer.
- Trial name
- STELLAR (NCT02533271)
- Testing
- Short-course radiotherapy with neoadjuvant chemotherapy, Long-term chemoradiotherapy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Chinese Academy of Medical Sciences
Rectal Neoplasms
Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer
The purpose of this phase II trial is to determine the efficacy and safety of the combination of oxaliplatin, capecitabine and radiotherapy as preoperative therapy in locally advanced cancers of the rectum.
- Trial name
- PROCTFUL (NCT00263029)
- Testing
- Oxaliplatin, Capecitabine, Radiotherapy
- Volunteers
- 18 people
- Sponsor
- Sanofi
Colon Cancer Liver Metastasis, Colon Cancer
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
The purpose of this study is to study the way radioembolization works by collecting biopsy samples of participants' tumors after the procedure.
- Conditions
- Colon Cancer Liver Metastasis, Colon Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT04668872
- Testing
- Y90 TARE, PET/CT, PET/MRI
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Cancer, Chemoradiotherapy
Non-OpeRative MANagement of Rectal Cancer Patients
This study is a single-center, open, prospective, single-treatment trial (pilot study). This study aims to analyze the treatment results after receiving capecitabine adjuvant chemotherapy for 4 months after non-surgical treatment…
- Conditions
- Rectal Cancer, Chemoradiotherapy, Watch & Wait
- Trial name
- NORMANDY (NCT04696757)
- Testing
- Capecitabine
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Kangbuk Samsung Hospital
Rectal Cancer
IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer
This is a prospective open label single-arm, single-institution phase II clinical trial to test the efficacy of neoadjuvant treatment with IXO (Irinotecan, Capecitabine [Xeloda], Oxaliplatin) followed by chemoradiotherapy and…
- Trial name
- IXOr (NCT01237665)
- Testing
- IXO regimen
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Ottawa Hospital Research Institute
Anal Squamous Cell Carcinoma
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer.
- Trial name
- MAESTRO (NCT06050707)
- Testing
- Radiotherapy - Low risk group, Radiotherapy - Standard risk group, Radiotherapy - Intermediate risk group
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 80 people
- Sponsor
- University Health Network, Toronto
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.
111Indium-labelled IPN01087 (111In-IPN01087) is developed as a radioactive diagnostic imaging agent in patients with colorectal or pancreatic cancer.
- Trial name
- NCT04632199
- Testing
- 111In-IPN01087 Low dose, 111In-IPN01087 High dose
- Where
- 5 sites in Belgium, France
- Sponsor
- Ipsen
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Rectal Cancer
Xeloda and Bevacizumab to Treat Rectal Cancer
The project objective is to evaluate the efficacy of the neoadjuvant treatment with bevacizumab, capecitabine and radiotherapy, in patients with rectal adenocarcinoma resectable locally advanced (stage T3 or T4), with or without…
- Trial name
- xeberecto (NCT00847119)
- Testing
- Bevacizumab, capecitabine (Xeloda), Rectal Radiotherapy
- Where
- Spain
- Volunteers
- 43 people
- Sponsor
- Institut Català d'Oncologia
Rectal Adenocarcinoma
Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
The purpose of the study is to determine the feasibility of using magnetic resonance imaging (MRI)-guided adaptive chemoradiation therapy to improve response to treatment.
- Trial name
- NCT05108428
- Testing
- Capecitabine, Radiation Therapy, FOLFOX regimen
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Rectal Cancer, Adenocarcinoma of the Rectum
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
The purpose of this study is determine the safety of 5-fluorouracil, bevacizumab and erlotinib when administered in combination with external beam radiation therapy(Phase I portion) as well as to begin to collect information…
- Trial name
- NCT00307736
- Testing
- 5-fluorouracil, bevacizumab, erlotinib
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Metastatic Colorectal Cancer
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
The purpose of this study is to test the safety and effectiveness of two investigational drugs (drugs that are not currently approved by the FDA) given in combination with radiation therapy or ablation.
- Trial name
- NCT03122509
- Testing
- durvalumab, tremelimumab, Radiotherapy (RT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Colorectal Cancer, pMMR
Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
The main objective of the SIRTCI study is to evaluate the safety and efficacy of the combination chemotherapy (XELOX: Capecitabine plus oxaliplatin), anti-angiogenic (Bevacizumab), SIRT (TheraSphere®) and ICI (Atezolizumab) in…
- Conditions
- Metastatic Colorectal Cancer, pMMR, MSS, Immune Checkpoint Inhibitor
- Trial name
- SIRTCI (NCT04659382)
- Testing
- Atezolizumab, Therasphere, XELOX
- Where
- 19 sites in France
- Volunteers
- 52 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Anal Cancer
Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00955240
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 20 sites in France
- Volunteers
- 16 people
- Sponsor
- UNICANCER